Therapeutic Value Articles & Analysis
13 news found
(“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS (“bYoRNA”) today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA (“mRNA”). Dyadic is a global biotechnology company focused on building innovative microbial ...
Vividion will continue its mission to unlock high value, traditionally undruggable target biology with precision therapeutics for cancers and immune disorders. ...
ByBayer AG
With this shift in our leadership team, we hope to continue our journey of rapid growth and expansion delivering world class iPSC-based solutions to therapeutic developers. We are continuing to build our leadership teams by recruiting Gustavo Mahler as Chief Executive Officer. ...
Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced that Jenna Goldberg, M.D., has ...
ByBayer AG
Tavros to receive $17.5M upfront, up to $430.5M in milestone payments for initial four programs, and certain royalties over agreement term / Vividion will have rights to opt-in to up to five more targets for up to $482M in additional payments /Partnership to define novel drug targets and biomarkers, in addition to positioning existing compounds Tavros Therapeutics, Inc., a ...
ByBayer AG
Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced that Aleksandra Rizo, M.D., Ph.D., ...
ByBayer AG
By addressing key limitations of conventional drug discovery techniques, Vividion’s proprietary chemoproteomic platform technology allows the company to unlock high value, traditionally undruggable target biology with precision therapeutics for cancers and immune disorders. ...
ByBayer AG
The transaction allows Neopharmed Gentili to strengthen its portfolio in the neuro-psychiatric area with high value-added drugs for the treatment of insomnia. Neopharmed Gentili, an Italian pharmaceutical company controlled by Ardian in partnership with the Del Bono family, which has historic roots in its territory and is pursuing international growth, announced that it has ...
“We are very pleased with these updated preliminary proof-of-concept efficacy and safety results, which we believe illustrate the therapeutic potential of zinc finger nuclease engineered cell therapy to address the current unmet needs of patients with sickle cell disease,” said Rob Schott, M.D., M.P.H, F.A.C.C, Head of Development at Sangamo. ...
Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs (G protein-coupled receptors) in disease-relevant ...
Orphan drug status is given to novel therapeutics treatments that demonstrate value in the treatment of rare diseases or conditions typically affecting fewer than 200,000 patients annually in the U.S. The designation provides Lung Therapeutics with several benefits, including a seven-year period of U.S. marketing exclusivity. About Lung ...
We work everyday to continue to build on and strengthen our IP portfolio to further enhance its potential value and therapeutic utility in a wide range of diseases, procedures, and ...
The licensing agreement allowed Jarvis and Geisler to commercialize certain aspects of their research, which involved the use of genetically engineered insect cells for manufacturing vaccines, diagnostics or therapeutics for use in human and veterinary medicine. GlycoBac uses the technology to create new genetically engineered insect cell lines optimized for this purpose. ...